Homophily and co-occurrence patterns shape randomized trials agendas: Illustration in antifungal agents

Journal of Clinical Epidemiology

Volumn 64, Issue 8, 2011, Pages 830-842

  Rizos, Evangelos C ^a   Salanti, Georgia ^b   Kontoyiannis, Dimitrios P ^c   Ioannidis, John P A ^b,d,e,f,g  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d INSTITUTE OF COMPUTER SCIENCE   (Greece)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphotericin; Anidulafungin; Antifungal; Azole; Caspofungin; Micafungin

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; PLACEBO; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDEMIA; CLINICAL RESEARCH; CO OCCURENCE ANALYSIS; DRUG COST; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; HOMOPHILY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; MEDICAL LITERATURE; METHODOLOGY; MYCOSIS; OROPHARYNX CANDIDIASIS; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE; SYSTEMIC MYCOSIS;

EID: 79959714410     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2010.11.017     Document Type: Article

References (54)

1. D.M. Caldwell, A.E. Ades, and J.P. Higgins Simultaneous comparison of multiple treatments: combining direct and indirect evidence BMJ 331 2005 897 900 (Pubitemid 41502718)
2. G. Salanti, J.P. Higgins, A.E. Ades, and J.P. Ioannidis Evaluation of networks of randomized trials Stat Methods Med Res 17 3 2008 279 301
3. G. Salanti, F.K. Kavvoura, and J.P. Ioannidis Exploring the geometry of treatment networks Ann Intern Med 148 2008 544 553 (Pubitemid 351665420)
4. T.J. Walsh, R.W. Finberg, C. Arndt, J. Hiemenz, C. Schwartz, and D. Bodensteiner Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group N Engl J Med 340 1999 764 771 (Pubitemid 29114295)
5. T.J. Walsh, P. Pappas, D.J. Winston, H.M. Lazarus, F. Petersen, J. Raffalli National Institute of Allergy and Infectious Diseases Mycoses Study Group Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 2002 225 234 (Pubitemid 34438861)
6. T.J. Walsh, H. Teppler, G.R. Donowitz, J.A. Maertens, L.R. Baden, and A. Dmoszynska Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med 351 2004 1391 1402
7. D.S. Krause, A.E. Simjee, C. van Rensburg, J. Viljoen, T.J. Walsh, and B.P. Goldstein A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis Clin Infect Dis 39 2004 770 775 (Pubitemid 39244288)
8. J.A. van Burik, V. Ratanatharathorn, D.E. Stepan, C.B. Miller, J.H. Lipton, D.H. Vesole National Institute of Allergy and Infectious Diseases Mycoses Study Group Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation Clin Infect Dis 39 2004 1407 1416 (Pubitemid 39518200)
9. J.A. Vazquez, D.J. Skiest, L. Nieto, R. Northland, I. Sanne, and J. Gogate A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS Clin Infect Dis 42 2006 1179 1186
10. E.R. Kuse, P. Chetchotisakd, C.A. da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao Micafungin Invasive Candidiasis Working Group Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 2007 1519 1527 (Pubitemid 46670281)
11. P.G. Pappas, C.M. Rotstein, R.F. Betts, M. Nucci, D. Talwar, and J.J. De Waele Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis Clin Infect Dis 45 2007 883 893 (Pubitemid 47580382)
12. A.C. Reboli, C. Rotstein, P.G. Pappas, S.W. Chapman, D.H. Kett, D. Kumar Anidulafungin Study Group Anidulafungin versus fluconazole for invasive candidiasis N Engl J Med 356 2007 2472 2482 (Pubitemid 46919773)
13. S.P. Borgatti, M.G. Everett, and L.C. Freeman Ucinet 6 for windows: software for social network analysis [Computer program] 2002 Analytic Technologies Harvard, MA
14. N.J. Gotelli, and G.L. Entsminger EcoSim: Null models software for ecology [Computer program] Version 7 2004 Acquired Intelligence Inc. and Kesey-Bear Jericho, VT
15. L. Stone, and A. Roberts The checkerboard score and species distribution Oecologia 85 1990 74 79
16. H.K. Johansen, and P.C. Gotzsche Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis JAMA 282 1999 1752 1759 (Pubitemid 29533606)
17. P.C. Gotzsche, and H.K. Johansen Meta-analysis of prophylactic or empiric antifungal therapy vs placebo or no treatment in cancer patients with neutropenia [Cochrane Review on CD-ROM] 1998 Cochrane Library Oxford, UK Update Software
18. D. Rennie Fair conduct and fair reporting of clinical trials JAMA 282 1999 1766 1768 (Pubitemid 29533609)
19. D. Rennie Correspondence: author reply. Improving the conduct and reporting of clinical trials JAMA 283 2000 2789 2790
20. G. Gartlehner, L. Morgan, P. Thieda, and A. Fleg The effect of study sponsorship on a systematically evaluated body of evidence of head-to-head trials was modest: secondary analysis of a systematic review J Clin Epidemiol 63 2010 117 125
21. S. Dias, N.J. Welton, and A.E. Ades Study designs to detect sponsorship and other biases in systematic reviews J Clin Epidemiol 63 2010 587 588
22. G. Gartlehner, and A. Fleg Comparative effectiveness reviews and the impact of funding bias J Clin Epidemiol 63 2010 589 590
23. S. Leucht, C. Corves, D. Arbter, R.R. Engel, C. Li, and J.M. Davis Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Lancet 373 2009 31 41
24. P. Gotzsche Are new drugs for schizophrenia better than old ones? Lancet 373 2009 1249 1250
25. P.A. Dieppe, S.J. Frankel, and B. Toth Is research into the treatment of osteoarthritis with non-steroidal anti-inflammatory drugs misdirected? Lancet 341 1993 353 354 (Pubitemid 23039710)
26. W.W. Woo, S.Y. Man, P.K. Lam, and T.H. Rainer Randomized double-blind trial comparing oral paracetamol and oral nonsteroidal antiinflammatory drugs for treating pain after musculoskeletal injury Ann Emerg Med 46 2005 352 361 (Pubitemid 41362565)
27. J.P. Ioannidis Perfect study, poor evidence: interpretation of biases preceding study design Semin Hematol 45 2008 160 166 (Pubitemid 351877088)
28. D.P. Kontoyiannis A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America Pharmacotherapy 21 8 Pt 2 2001 175S 187S (Pubitemid 32727044)
29. T.J. Walsh, E.J. Anaissie, D.W. Denning, R. Herbrecht, D.P. Kontoyiannis, and K.A. Marr Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America Clin Infect Dis 46 2008 327 360 (Pubitemid 351265310)
30. P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin Jr., T.F. Calandra, and J.E. Edwards Jr. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 48 2009 503 535
31. S. Harbarth, S.L. Pestotnik, J.F. Lloyd, J.P. Burke, and M.H. Samore The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy Am J Med 111 2001 528 534 (Pubitemid 33052350)
32. G. Deray Amphotericin B nephrotoxicity J Antimicrob Chemother 49 Suppl 1 2002 37 41 (Pubitemid 34162655)
33. H.K. Johansen, and P.C. Gotzsche Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia Cochrane Database Syst Rev 3 2000 CD000969
34. J. Peppercorn, E. Blood, E. Winer, and A. Partridge Association between pharmaceutical involvement and outcomes in breast cancer clinical trials Cancer 109 2007 1239 1246 (Pubitemid 46466549)
35. J.P. Ioannidis Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses CMAJ 181 8 2009 488 493
36. G.J. Timmers, S. Zweegman, A.M. Simoons-Smit, A.C. van Loenen, D. Touw, and P.C. Huijgens Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial Bone Marrow Transplant 25 2000 879 884 (Pubitemid 30209682)
37. G.N. Mattiuzzi, E. Estey, I. Raad, F. Giles, J. Cortes, and Y. Shen Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome Cancer 97 2003 450 456 (Pubitemid 36133812)
38. G. Biancofiore, M.L. Bindi, R. Baldassarri, A.M. Romanelli, G. Catalano, and F. Filipponi Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study Transpl Int 15 2002 341 347 (Pubitemid 36068187)
39. Datamonitor pharmaceutical report 2007, Available at www.piribo.com/ publications/diseases-conditions/skin/commercial-pipeline-insight-systemic- antifungals.html. Accessed November, 2007.
40. Available at http://www.marketresearch.com/map/prod/1002429.html. Accessed May, 2004.
41. Available at www.pfizer.com/investors/financial-reports/financial- reports.jsp. Accessed, 2008.
42. A.V. Kulkarni, J.W. Busse, and I. Shams Characteristics associated with citation rate of the medical literature PLoS ONE 2 5 2007 e403
43. B.M. Psaty, C.D. Furberg, W.A. Ray, and N.S. Weiss Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis JAMA 292 2004 2622 2631 (Pubitemid 39577518)
44. N.K. Choudhry, H.T. Stelfox, and A.S. Detsky Relationships between authors of clinical practice guidelines and the pharmaceutical industry JAMA 287 2002 612 617 (Pubitemid 34252013)
45. K. Morin, H. Rakatansky, F.A. Riddick Jr., L.J. Morse, J.M. O'Bannon 3rd, and M.S. Goldrich Managing conflicts of interest in the conduct of clinical trials JAMA 287 2002 78 84 (Pubitemid 34251679)
46. S. Eckermann, J. Karnon, and A.R. Willan The Value of Value of Information: Best Informing Research Design and Prioritization Using Current Methods Pharmacoeconomics 28 9 2010 699 709
47. C. Schmidt Researchers consider value-of-information theory for selecting trials J Natl Cancer Inst 102 2010 144 146
48. A. Willan, and M. Kowgier Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods Clin Trials 5 4 2008 289 300
49. S.D. Ramsey, D.K. Blough, and S.D. Sullivan A forensic evaluation of the National Emphysema Treatment Trial using the expected value of information approach Med Care 46 2008 542 548
50. E. Fenwick, K. Claxton, and M. Sculpher The value of implementation and the value of information: combined and uneven development Med Decis Making 28 2008 21
51. T.E. Colbourn, C. Asseburg, L. Bojke, Z. Philips, N.J. Welton, and K. Claxton Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses BMJ 335 2007 655
52. K.P. Claxton, and M.J. Sculpher Using value of information analysis to prioritise health research: some lessons from recent UK experience Pharmacoeconomics 24 2006 1055 1068 (Pubitemid 44683363)
53. A.R. Willan, and E.M. Pinto The value of information and optimal clinical trial design Stat Med 24 2005 1791 1806 (Pubitemid 40872643)
54. D.N. Lathyris, N.A. Patsopoulos, G. Salanti, and J.P. Ioannidis Industry sponsorship and selection of comparators in randomized clinical trials Eur J Clin Invest 40 2 2010 172 182